Fixation Using Alternative Implants for the Treatment of Hip Fractures (FAITH-2) (FAITH-2)
Femoral Neck Fractures
About this trial
This is an interventional treatment trial for Femoral Neck Fractures
Eligibility Criteria
Inclusion Criteria
- Adult men or women ages 18 to 60 years.
- Fracture of the femoral neck.
- Fracture amenable to both surgical treatments (SHS and cancellous screws).
- Operative treatment within 7 days of injury.
- Provision of informed consent by patient or substitute decision maker.
Exclusion Criteria
- Patients with previously diagnosed osteoporosis.
- Fracture-dislocation of the femoral neck and hip joint.
- Planned antegrade nailing of an ipsilateral femoral shaft fracture (if present).
- Current infection around the hip (i.e. soft tissue or bone).
- Stress fracture of the femoral neck.
- Pathologic fractures secondary to neoplasm or other bone lesion.
- Patients with known or likely undiagnosed disorders of bone metabolism such as Paget's disease, osteomalacia, osteopetrosis, osteogenesis imperfect, etc.
- Patients with hyperhomocysteinemia.
- Patient has an allergy to vitamin D or another contraindication to being prescribed vitamin D.
- Patient is currently taking an over counter drug and/or food supplement that contains vitamin D and is unable or unwilling to discontinue its use for this study.
- Likely problems, in the judgment of the attending surgeon, with maintaining follow up (e.g. patients with no fixed address, plans to move out of town). This may include patients with severe mental disorders and drug addictions without adequate support.
- Pregnancy.
- Patient is incarcerated.
- Patient is not expected to survive injuries.
- The attending surgeon believes the patient should be excluded because they are involved in a conflicting clinical trial.
Sites / Locations
- The Center for Orthopedic Research and Education (CORE) Institute
- University of California, San Francisco
- University of Florida
- Indiana University (IU Health Methodist Hospital)
- University of Maryland, Baltimore
- University of Michigan
- Hennepin Healthcare System
- Allegheny-Singer Research Institute
- Inova Health Care Services
- West Virginia University
- Alfred Health
- Royal Columbian Hospital
- University of British Columbia & Vancouver Costal Health Authority
- Health Sciences Centre Winnipeg
- Memorial University
- Hamilton Health Sciences
- Kingston General Hospital
- Ottawa Hospital Research Institute
- Sunnybrook Research Institute
- St. Michael's Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Sliding Hip Screw and Vitamin D supplementation
Sliding Hip Screw and Vitamin D placebo
Cancellous Screws and Vitamin D supplementation
Cancellous Screws and Vitamin D placebo
Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.
Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.